StockStory.org on MSN
Teleflex (NYSE:TFX) Misses Q4 Sales Targets, Stock Drops
Medical technology company Teleflex (NYSE:TFX) in Q4 CY2024 as sales rose 2.8% year on year to $795.4 million. Its non-GAAP ...
New, independent, publicly traded company (NewCo) consisting of Teleflex’s Urology, Acute Care, and OEM businesses. RemainCo will consist of Teleflex’s Vascular Access, Interventional, and Surgical ...
In the last three months, 5 analysts have published ratings on Teleflex (NYSE:TFX), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results